Abstract:Hepatitis B virus (HBV) infection is an important public health issue. Hong Kong's universal HBV immunisation programme for newborns began in 1988.1 This programme consists of administering hepatitis B immunoglobulin (HBIg) to infants born to hepatitis B surface antigen (HBsAg)–positive mothers, along with the first dose of the HBV vaccine at birth. The second and third doses of the vaccine are typically given in Maternal and Child Health Centres at 1 and 6 months, respectively. Notably, the proportion of HBsAg-positive pregnant women has steadily decreased in recent years, from 5.2% in 20162 to 2.4% in 2023 (unpublished data). Despite a 99.8% HBsAg screening rate among antenatal women, together with 99.5% coverage for both HBIg and HBV vaccinations in newborns of HBsAg-positive mothers,2 a local study3 of 641 HBsAg-positive pregnant women showed that the overall mother-to-child transmission (MTCT) rate remained 1.1%, indicating immunoprophylaxis failure. To align with the World Health Organization's (WHO) goal of eliminating viral hepatitis as a public health threat by 2030,4 and specifically to achieve the WHO target of <0.1% HBsAg prevalence among 5-year-old children by that year, further reduction of MTCT of HBV has been targeted by the multidisciplinary Steering Committee on Prevention and Control of Viral Hepatitis, established in 2018 and chaired by the Director of Health and the Chief Executive of Hospital Authority.5 As an obstetrics representative on the Steering Committee, the first author had the opportunity to present a literature review for use in formulating the action plan. Three strategies were considered: (1) maintaining the current approach of administering HBIg and HBV vaccinations to newborns of HBsAg-positive mothers, (2) conducting another randomised controlled trial on the use of tenofovir in further prevention of MTCT of HBV, and (3) implementing a universal programme to use tenofovir for this purpose. Although two major randomised controlled trials,6 7 both published in The New England Journal of Medicine , appeared to reach conflicting conclusions, the MTCT of HBV rates were zero in both the Mainland China study6 (n=92, per-protocol) and the Thailand study7 (n=147). The safety of tenofovir in pregnancy has also been established. Rebound increases in alanine aminotransferase after tenofovir discontinuation were mild in most cases (acute hepatic exacerbation, defined as alanine aminotransferase elevation of >300 IU/L, occurred in 6% of the tenofovir group vs 3% of the control group7). The administration of antivirals to HBsAg-positive pregnant women with high HBV DNA levels has been recommended by the American Association for the Study of Liver Diseases, European Association for the Study of the Liver, Asian Pacific Association for the Study of the Liver, and Advisory Committee on Immunization Practices.5 Despite these recommendations, the WHO had not made any recommendations by 2018. The Steering Committee ultimately decided to proceed with option 3.5

Viral Hepatitis Elimination in Infants, Children, and Pregnancy: Elimination for Everyone by Everyone

Viral Hepatitis in Pregnant Mexican Women: Its Impact in Mother-Child Binomial Health and the Strategies for Its Eradication

Hepatitis B and C in pregnancy: a review and recommendations for care

Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps

[Getting to Zero Mother-to-child Transmission of Hepatitis B Virus: Dream and Challenge].

Overview of Hepatitis C in Pregnancy: Screening, Management and Treatment

Elimination of Hepatitis B Virus Infection in Children: Experience and Challenge in China

Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders

Management and Elimination of mother-to-child transmission of hepatitis B virus: A therapeutical Approach

Vertical transmission of hepatitis B virus: propositions and future directions

Global Elimination of Hepatitis C Virus

Issues Meriting Further Study in Preventing Mother-to-Infant Transmission of Hepatitis B by Antiviral Therapy During Pregnancy

Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy

[A Survey of the Current Status of Research on the Diagnosis and Treatment of Hepatitis C Virus Antibody-Positive Pregnant Women].

Can we eliminate mother-to-child transmission of hepatitis B virus in Hong Kong by 2030?

Navigating Perinatal Challenges: A Comprehensive Review of Hepatitis B Viral Infection and Pregnancy Outcomes

Best practices for hepatitis C linkage to care in pregnant and postpartum women: perspectives from the Treatment In Pregnancy for Hepatitis C Community of Practice

Hepatitis B infection and immunity in Migrant Children and Pregnant Persons in Europe: A Systematic Review and Meta-Analysis

Viral Hepatitis in Pregnancy: ACOG Clinical Practice Guideline No. 6.

Hepatitis elimination by 2030: Progress and challenges

Hepatitis B Elimination Globally-The Answer May Not Be the Same for Everyone